Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | PGD | P52209 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837493 | 1.00 | SLC22A6 (0.50) | SLC22A6MAPK1MAPTGABRR1PGD | |
| SCHEMBL9395777 | 1.00 | SLC22A6 (0.50) | SLC22A6MAPK1MAPTGABRR1PGD | |
| SCHEMBL9395053 | 0.90 | SLC22A6 (0.44) | SLC22A6MAPK1MAPTGABRR1PGD | |
| SCHEMBL9395792 | 0.90 | SLC22A6 (0.44) | SLC22A6MAPK1MAPTGABRR1PGD | |
| SCHEMBL9393935 | 0.90 | SLC22A6 (0.44) | SLC22A6MAPK1MAPTGABRR1PGD | |
| SCHEMBL9395761 | 0.84 | MAPK1 (0.42) | SLC22A6MAPK1MAPTPGDKDM4E | |
| SCHEMBL10417537 | 0.78 | MAPK1 (0.48) | SLC22A6MAPK1PGDGPR84ALDH1A1 | |
| SCHEMBL26811369 | 0.78 | MAPK1 (0.48) | SLC22A6MAPK1PGDGPR84ALDH1A1 | |
| SCHEMBL1982314 | 0.78 | MAPK1 (0.65) | MAPK1KDM4EALDH1A1TDP1GRN | |
| SCHEMBL29036580 | 0.77 | MAPK1 (0.41) | SLC22A6MAPK1MAPTGABRR1PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468448-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-20050256322-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1589018-A1 | PROCESS FOR PRODUCING HEXAHYDROFUROFURANOL DERIVATIVE, INTERMEDIATE THEREOF AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-6867321-B2 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-0745681-B1 | Optical resolution of chlorohydrin with microorganism | DAISO CO LTD (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5776766-A | Optical resolution of chlorohydrin with microorganism | DAISO CO., LTD. (JP) | 1998-07-07 | — | — | US | disclosed |
| EP-0745681-A2 | Optical resolution of chlorohydrin with microorganism | DAISO CO., LTD. (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0385733-B1 | Process for preparing optically active 6-t-butoxy-3,5-dihydroxyhexanoic esters | TAKASAGO PERFUMERY CO LTD (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-4994602-A | Process for preparing optically active 6-t-butyoxy-3,5-dihydroxyhexanoic esters | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0385733-A2 | Process for preparing optically active 6-t-butoxy-3,5-dihydroxyhexanoic esters | Takasago International Corporation (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256322-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | SLC22A6 4438/4885MAPK1 3464/4885MAPT 3733/4885 |
| US-20040162340-A1 | Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof | CYP4F11, CYP51A1, CYP4A11 | SLC22A6 4460/4885MAPK1 3405/4885MAPT 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.